Renal Adjuvant MultiPle Arm Randomised Trial (RAMPART): An international investigator-led phase III multi-arm multi-stage multi-centre randomised controlled platform trial of adjuvant therapy in patients with resected primary renal cell carcinoma (RCC) at high or intermediate risk of relapse

Trial status: Authorised Metastasis Free Survival (MFS), defined as the interval from randomisation to first evidence of metastases or death from RCC., RCC specific survival time, defined as the time from randomisation to death from RCC., Quality of life, Toxicity, Patient preferences for adjuvant immunotherapy Disease Free Survival - defined as the interval from randomisation to first evidence of local recurrence, new primary RCC, distant metastases, or death from any cause, whichever occurs first., Overall Survival - defined as all-cause mortality, the time from randomisation to death from any cause (including RCC).

Metastasis Free Survival (MFS), defined as the interval from randomisation to first evidence of metastases or death from RCC., RCC specific survival time, defined as the time from randomisation to death from RCC., Quality of life, Toxicity, Patient preferences for adjuvant immunotherapy

Age group: 65+ years, 18-64 years Gender: Female, Male Target enrollment: 203 participants